Bracco Diagnostics

November 17, 2020 — Bracco Diagnostics Inc. announced it will be showcasing its full portfolio of diagnostic imaging ...

January 17, 2020 — Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., one of the world’s leading ...

Bracco Diagnostics Inc. announced U.S. Food and Drug Administration (FDA) approval for Varibar Thin Liquid (barium sulfate) for oral suspension, which is indicated for modified barium swallow (MBS) studies. The contrast agent is used to detect and assess the type and severity of swallowing disorders also known as dysphagia.

Bracco Imaging S.p.A. has signed a definitive agreement to acquire Blue Earth Diagnostics, a molecular imaging company based in Oxford, U.K. Subject to customary closing conditions, completion of the transaction is expected in the third quarter of this calendar year.

Physicians and technologists at Children’s Hospital of Philadelphia (CHOP) will be able to conduct research and education on the use of contrast ultrasound thanks to a $300,000 grant from Bracco Diagnostics Inc. USA. Contrast ultrasound is a relatively new technology that was only approved for use in pediatric patients in 2016. CHOP is among the first pediatric hospitals to use this technology in the U.S.